Preclinical mouse cancer models: a maze of opportunities and challenges.
about
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewGenetics and biology of pancreatic ductal adenocarcinomaLeveraging big data to transform target selection and drug discoveryOptimized design and analysis of preclinical intervention studies in vivoEfficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical DataAndrogen receptor splice variants and prostate cancer: From bench to bedside.Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis.Fusion between cancer cells and macrophages occurs in a murine model of spontaneous neu+ breast cancer without increasing its metastatic potential.UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology.Patient-derived induced pluripotent stem cells in cancer research and precision oncology.Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?Computational models for predicting drug responses in cancer research.Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Nanomaterial-Enabled Cancer Therapy.Genetically engineered mouse models of melanoma.Models of Models: A Translational Route for Cancer Treatment and Drug Development.Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors.Generating Genetically Modified Mice: A Decision Guide.A structural perspective on the interactions of TRAF6 and Basigin during the onset of melanoma: A molecular dynamics simulation study.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.Stem Cell Pathology.Preclinical mouse solid tumour models: status quo, challenges and perspectives.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Levo-Corydalmine Alleviates Neuropathic Cancer Pain Induced by Tumor Compression via the CCL2/CCR2 Pathway.Patient-derived xenograft models in musculoskeletal malignancies.Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.
P2860
Q26741651-C93BBDB4-8BBC-470C-BC2E-90D61DE8A194Q26765438-7BC983E2-E585-45A3-B22F-34340D8E51CBQ26776403-B306B0BB-137C-44D2-BF64-0283CDF8BFA7Q28595545-DEAEA7EE-3462-44E5-9AB4-1BAEDA99F5F6Q31112729-06157295-F8AB-47CD-804F-D5CD6D13C690Q33567024-47841ABD-F1EB-4968-8530-B457A1A3AF9BQ36739725-A1484A58-C19A-40DA-A57C-B12FA9B93039Q36876967-845AD7A4-CF5E-4C7C-A385-E27C2D2DC477Q37013343-78DDC4D2-4590-4F53-8A8B-AD3CD82FC429Q37641521-2E02EDA3-E452-4252-A045-7B0A4D85ABA9Q38708831-6C4E3D1E-867C-406E-8198-B266237B9875Q38729611-49605B3F-9770-48B5-AA74-CF6F0576487BQ38786566-5BA011EE-F337-47B1-98F1-473BDB4E95DFQ38795629-241126C3-B418-45E2-BD4F-CC37EB5E415EQ38822873-DC8BF3B1-C5EA-45EF-BD48-AFFB6C8D9063Q38904995-3ADAEBAF-28E6-48D4-9B5A-679A0E1AF42DQ39028343-78CEE9DC-8C5D-409C-9D41-72AE42F2151FQ39323096-7B9DA753-D7E3-4B75-BF3D-F88376BF19DDQ39329577-DBB764DE-C708-4C53-ABD8-95F9DF9FF3C3Q41833969-B44488C0-31F4-478F-8A95-C98C914BB3D2Q42093899-0EDE51F3-AF1B-4FAF-BC5F-CC8AC9E3124CQ44456046-45AE3CA5-8600-4072-97B5-4CE5E2792C22Q46914962-4690D9E5-5DDD-4416-A234-2E133F0BC770Q47228068-EBB373D0-C93A-463B-AE32-66B9773C5E64Q47547587-7DDCA117-2D2D-4F6E-A6D3-2A9D3FE01E86Q47564988-4853A44F-68C7-4BB2-BE1E-09C6C87CF7CDQ47786670-C0B7932C-ACCA-48F3-8724-D04A0E2D82DEQ48059710-675A9A02-DD3A-49D8-8D95-E61052AD5DD5Q48089417-8CB4A1CA-36DC-44E8-8EC5-8A98797901F6Q48558433-B6404436-4436-4A3F-B817-22D031F67CACQ49832498-459CDA08-78A9-47C4-B452-2E8F2ACC78AEQ49876859-2768F328-D56B-46DD-981C-1D906E33BD2BQ49897464-AEA4E5E3-2A0A-481F-B10B-A34AB76C276BQ50068467-AEC88546-459D-4732-A40E-B8A7F2B46DE8Q50096902-42CAE5CC-C309-4729-849F-8C6338C6B54FQ50422486-EA2FD686-1A32-4CA0-B423-E7DFF837B7DBQ50956794-D6F52144-242C-453F-9FC4-D92FB3A8A4C2Q52311090-D051A67C-9082-4A34-8908-E06047E20A3EQ52313265-D9A2E341-83BC-4A03-A50F-A52396C4CA52Q52594999-E671A175-4CFB-43A1-A9C7-FEFE9BDA978A
P2860
Preclinical mouse cancer models: a maze of opportunities and challenges.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Preclinical mouse cancer models: a maze of opportunities and challenges
@nl
Preclinical mouse cancer models: a maze of opportunities and challenges.
@ast
Preclinical mouse cancer models: a maze of opportunities and challenges.
@en
type
label
Preclinical mouse cancer models: a maze of opportunities and challenges
@nl
Preclinical mouse cancer models: a maze of opportunities and challenges.
@ast
Preclinical mouse cancer models: a maze of opportunities and challenges.
@en
prefLabel
Preclinical mouse cancer models: a maze of opportunities and challenges
@nl
Preclinical mouse cancer models: a maze of opportunities and challenges.
@ast
Preclinical mouse cancer models: a maze of opportunities and challenges.
@en
P2093
P2860
P3181
P1433
P1476
Preclinical mouse cancer models: a maze of opportunities and challenges.
@en
P2093
Chi-Ping Day
Glenn Merlino
Terry Van Dyke
P2860
P3181
P356
10.1016/J.CELL.2015.08.068
P407
P577
2015-09-01T00:00:00Z